维普中文期刊产品整合服务
162篇 您的检索式:作者名="Baselga M"
    题名 作者 年代 出处 被引量
1系统性药物治疗儿童银屑病的安全性显示文摘银屑病是一种常见的慢性炎症性皮肤病。成年人的发病率为2%~3%,其中大约有三分之一的患者在18岁之前发病。在儿童期,该病的发病率呈线性增长。从1970年至2000年,儿童银屑病的发病率增加了一倍多。尽管对许多轻度银屑病患儿而言,局部治疗已足够,但对更多可能影响生活质量的重度或顽固性的银屑病患儿,则往往需要系统性治疗。bronckers imgj seyger mmb west dp lara-corrales i tollefson m tom wl hogeling m belazarian l zachariae c mahé e siegfried e philipp s szalai z vleugels ra holland k murphy r baselga e cordoro k lambert j alexopoulos a mrowietz u kievit w paller as 邓婕(编译) 张锡宝(审校) 2017皮肤性病诊疗学杂志2017,24,5:3
2Everolimus in postmenopausal hormone-receptor-positive advanced breast Cancer显示文摘Baselga J Campone M Piccart M 0,,06:1
3Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy:a case series显示文摘Baselga E Cordisco MR Garzon M 2008Br J Dermatol2008,158,6:1
4Phase I safety,pharmacokinetic, and pharmaeodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyroslne kinase inhibitor, in patients with five selected solid tumor types显示文摘BASELGA J RISCHIN D RANSON M 2002J Clin Oncol2002,20,21:1
5Does storage time in LN2infiuence survival and pregnancy outcome of vitrified rabbit embryos?显示文摘Lavara R Baselga M Vicente JS 2011Theriogenology2011,76,:1
6Everolimus inpostmenopausal hormone- receptor- positive advanced breast cancer显示文摘Baselga J Campone M Piccart M 2012N Engl J Med2012,366,6:1
7Everolimus in postmenopausal hormone receptor positive advanced breast cancer显示文摘Baselga J Campone M Piccart M 2012New England Journal of Medicine2012,366,6:1
8The epidermal growth factor receptor pathway:a model for targeted therapy显示文摘Scaltriti M Baselga J 2006Clin Cancer Res2006,12,:1
9Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types 显示文摘Baselga J Rischin D Ranson M 2002J Clin Onco2002,20,21:1
10Everolimus in postmeno- pausal hormone- receptor- positive advanced breast cancer 显示文摘Baselga J Campone M Piceart M 2012N Engl J Med2012,366,6:1
11Targeted therapies for breast cancer 显示文摘Higgins M J Baselga J 2011J Clin Invest2011,121,:1
12Phase Ⅰ safety pharmacokinetic and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types显示文摘Baselga J Rischin D Ranson M 2002J Clin Oncol2002,20,:1
13Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘Baselga J Campone M Piccart M 2012N Engl J Med2012,366,6:1
14Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer 显示文摘BASELGA J CAMPONE M PICCART M 2012New Eng J Med2012,366,6:1
15Everolimus in postmeno- pausal hormone-receptor-positive advanced breast cancer 显示文摘Baselga J Campone M Piccart M 2012N Engl J Med2012,366,6:1
16Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘Baselga J Campone M Piccart M 0,,06:1
17Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer 显示文摘Baselga J Segalla JG Roch6 H Del Giglio A Pinczowski H Ciruelos EM Filho SC G6mez P Van Eyll B Bermejo B Llombart A Garicochea B Durdn Md Hoff PM Espi6 M de Moraes AA Ribeiro RA Mathias C Gil Gil M Ojeda B Morales J Kwon Ro S Li S Costa F 2012J Clin Oncol2012,30,13:1
18Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘BASELGA J CAMPONE M PICCART M 2012N Engl J Med2012,366,6:1
19Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer显示文摘Baselga J Zambetti M Llombart-Cussac A 2009J Clin Oncol2009,27,4:1
20Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘Baselga J Campone M Piccart M 2012N Engl J Med2012,366,6:1
返回顶部 每页显示:
共9页 首页 上一页 第1页 下一页 末页 /9 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费